Peter HÃ,gh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11743042/publications.pdf

Version: 2024-02-01

47 1,337 21 34 g-index

48 48 48 2002 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 50, 443-453.	2.6	210
2	EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 1359-1371.	2.6	100
3	Effect of aerobic exercise on physical performance in patients with Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1207-1215.	0.8	76
4	Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurology, 2018, 75, 1114.	9.0	75
5	Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. Experimental Gerontology, 2019, 121, 91-98.	2.8	72
6	Microstates as Disease and Progression Markers in Patients With Mild Cognitive Impairment. Frontiers in Neuroscience, $2019,13,563.$	2.8	53
7	Change in Fitness and the Relation to Change in Cognition and Neuropsychiatric Symptoms After Aerobic Exercise in Patients with Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 137-145.	2.6	45
8	Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2016, 42, 146-158.	1.5	40
9	Patients with Alzheimer's disease who carry the <i>APOE</i> ε4 allele benefit more from physical exercise. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 99-106.	3.7	40
10	A multidisciplinary memory clinic in a neurological setting: diagnostic evaluation of 400 consecutive patients. European Journal of Neurology, 1999, 6, 279-288.	3.3	37
11	Diagnostic profile of young and middle-aged memory clinic patients. Neurology, 2002, 59, 1259-1262.	1.1	35
12	Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative Dementias. Journal of Alzheimer's Disease, 2020, 75, 429-436.	2.6	35
13	Autonomic Dysfunction in Patients with Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 681-689.	2.6	31
14	Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers. Dementia and Geriatric Cognitive Disorders, 2016, 42, 80-92.	1.5	30
15	Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer's disease. Clinical Neurophysiology, 2019, 130, 1889-1899.	1.5	30
16	Associations between physical function, dual-task performance and cognition in patients with mild Alzheimer's disease. Aging and Mental Health, 2016, 20, 1139-1146.	2.8	28
17	Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the 1µ4 Allele on Regional Cerebral Blood Flow. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 42-51.	2.3	27
18	A 16-Week Aerobic Exercise Intervention Does Not Affect Hippocampal Volume and Cortical Thickness in Mild to Moderate Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 293.	3.4	27

#	Article	IF	CITATIONS
19	Electroencephalographic Cross-Frequency Coupling as a Sign of Disease Progression in Patients With Mild Cognitive Impairment: A Pilot Study. Frontiers in Neuroscience, 2020, 14, 790.	2.8	27
20	Discrepancy between stimulus response and tolerance of pain in Alzheimer disease. Neurology, 2015, 84, 1575-1581.	1.1	25
21	Decreased Parietal Beta Power as a Sign of Disease Progression in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 65, 475-487.	2.6	25
22	The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer $\hat{a} \in \mathbb{N}$ s disease $\hat{a} \in \mathbb{N}$ a cross-sectional study. BMC Geriatrics, 2020, 20, 513.	2.7	24
23	Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 284-290.	3.7	23
24	Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. EBioMedicine, 2021, 67, 103361.	6.1	23
25	Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease. Brain and Behavior, 2020, 10, e01630.	2.2	22
26	Moderate―to highâ€intensity exercise does not modify cortical βâ€amyloid in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 208-215.	3.7	20
27	Functional Brain Imaging With Single-Photon Emission Computed Tomography in the Diagnosis of Alzheimer's Disease. International Psychogeriatrics, 1997, 9, 223-227.	1.0	19
28	Altered Low-Frequency EEG Connectivity in Mild Cognitive Impairment as a Sign of Clinical Progression. Journal of Alzheimer's Disease, 2019, 68, 947-960.	2.6	19
29	Temporal Lobe Hypoperfusion in Isolated Amnesia with Slow Onset: A Single Photon Emission Computer Tomography Study. Dementia and Geriatric Cognitive Disorders, 2004, 18, 15-23.	1.5	15
30	A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease. Journal of the Neurological Sciences, 2020, 410, 116645.	0.6	15
31	Brief Assessment of Impaired Cognition (BASIC)â€"Validation of a new dementia caseâ€finding instrument integrating cognitive assessment with patient and informant report. International Journal of Geriatric Psychiatry, 2019, 34, 1724-1733.	2.7	14
32	Quantitative Electroencephalography Analyzed by Statistical Pattern Recognition as a Diagnostic and Prognostic Tool in Mild Cognitive Impairment: Results from a Nordic Multicenter Cohort Study. Dementia and Geriatric Cognitive Disorders Extra, 2019, 8, 426-438.	1.3	14
33	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. Journal of Alzheimer's Disease, 2020, 75, 937-947.	2.6	13
34	Visual Rating and ROI-Based Parametric Analysis of rCBF SPECT in Patients with Mild or Questionable Dementia: A Comparative Study. Dementia and Geriatric Cognitive Disorders, 2007, 24, 429-433.	1.5	10
35	Progressive DNA and RNA damage from oxidation after aneurysmal subarachnoid haemorrhage in humans. Free Radical Research, 2018, 52, 51-56.	3.3	9
36	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. Frontiers in Aging Neuroscience, 2021, 13, 659898.	3.4	9

#	Article	IF	CITATIONS
37	Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. Psychiatry Research - Neuroimaging, 2020, 302, 111099.	1.8	9
38	Physical Exercise May Increase Plasma Concentration of High-Density Lipoprotein-Cholesterol in Patients With Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 532.	2.8	3
39	Sixteen Weeks of Aerobic Exercise does not Alter Resting-state Connectivity of the Precuneus in Patients with Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 171-177.	1.4	3
40	O5-04-06: Moderate to high-intensity physical exercise in patients with Alzheimer's disease. , 2015, 11, P324-P325.		2
41	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients. Journal of Alzheimer's Disease Reports, 2022, 6, 121-127.	2.2	2
42	Cerebrospinal fluid and saliva lactoferrin as a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population. Alzheimer's and Dementia, 2021, 17, .	0.8	1
43	Potentially Reversible Conditions in Memory Clinic Patients. , 0, , 123-128.		0
44	P4-059: CEREBROSPINAL FLUID ROUTINE PARAMETERS AND BIOMARKERS AS POTENTIAL INDICATORS OF CLINICAL PROGRESSION IN MILD COGNITIVE IMPAIRMENT. , 2014, 10, P803-P804.		0
45	P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid- \hat{l}^2 1-42 levels in patients with Alzheimer's disease. , 2015, 11, P364-P365.		0
46	[P3–174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1000.	0.8	0
47	Detecting seizure patterns in patients with Alzheimer's disease using longâ€ŧerm EEG monitoring: A feasibility study. Alzheimer's and Dementia, 2020, 16, e042025.	0.8	0